Shopping Cart
- Remove All
- Your shopping cart is currently empty
Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin that simultaneously targets the delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) signaling pathways. Dilpacimab has significant potential in cancer research due to its dual targeting of tumor angiogenesis and Notch signaling.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $579 | In Stock | |
5 mg | $1,580 | In Stock | |
10 mg | $2,530 | In Stock | |
25 mg | $3,750 | In Stock | |
50 mg | $4,960 | In Stock |
Description | Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin that simultaneously targets the delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) signaling pathways. Dilpacimab has significant potential in cancer research due to its dual targeting of tumor angiogenesis and Notch signaling. |
Synonyms | PR1283233, PR 1283233, ABT-165, ABT165 |
Cas No. | 1791420-09-1 |
Color | Transparent |
Appearance | Liquid |
Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.